Related Experiment Video
Updated: Feb 27, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
AR C-106T gene polymorphism and diabetic nephropathy in the Eastern Asians with T2DM: A meta-analysis including 2120
Yan-Yan Li1, Hui Wang2, Xin-Xing Yang1
1Department of Gerontology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Background:
Aldose reductase (AR) gene C-106T polymorphism may be associated with diabetic nephropathy (DN) susceptibility, but the results of individual studies remain controversial.
Objective And Methods:
To explore the relationship between AR gene C-106T gene polymorphism and DN in the Eastern Asians with type 2 diabetes mellitus (T2DM) population, we conducted a meta-analysis of 2120 participants from 5 studies. Pooled odds ratio (ORs) and the corresponding 95% confidence interval (95% CI) were evaluated by either a fixed or random-effects models.
Results:
AR C-106T gene polymorphism was significantly associated with DN in the Eastern Asians population with T2DM under allelic (OR: 1.81, 95% CI: 1.30-2.52, P=0.0005), recessive (OR: 1.88, 95% CI: 1.20-2.97, P=0.006), dominant (OR: 9.22, 95% CI: 2.73-31.12, P=0.0003), homozygous (OR:2.27, 95% CI: 1.43-3.61, P=0.0005), heterozygous (OR: 5.75, 95% CI: 1.96-16.81, P=0.001), and additive genetic models (OR: 2.27, 95% CI: 1.48-3.48, P=0.0002).
Conclusions:
In the Eastern Asians with T2DM, the AR gene C-106T gene polymorphism is correlated with an increased risk of DN. The Eastern Asians with the T allele of AR gene C-106T gene polymorphism might be susceptible to DN.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

